Compare TISI & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TISI | STXS |
|---|---|---|
| Founded | 1973 | 1990 |
| Country | United States | United States |
| Employees | 6800 | N/A |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 139.3M |
| IPO Year | 1995 | 2004 |
| Metric | TISI | STXS |
|---|---|---|
| Price | $24.96 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 37.1K | ★ 482.6K |
| Earning Date | 11-11-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $896,483,000.00 | $29,346,617.00 |
| Revenue This Year | N/A | $6.04 |
| Revenue Next Year | N/A | $33.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $12.34 | $1.05 |
| 52 Week High | $29.57 | $3.19 |
| Indicator | TISI | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 24.62 |
| Support Level | $15.93 | N/A |
| Resistance Level | $28.05 | $1.98 |
| Average True Range (ATR) | 1.23 | 0.05 |
| MACD | -0.65 | -0.01 |
| Stochastic Oscillator | 3.84 | 5.00 |
Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.